DK3049059T3 - Intranasal dhe formulering til behandlingen af hovedpine - Google Patents

Intranasal dhe formulering til behandlingen af hovedpine Download PDF

Info

Publication number
DK3049059T3
DK3049059T3 DK14830861.2T DK14830861T DK3049059T3 DK 3049059 T3 DK3049059 T3 DK 3049059T3 DK 14830861 T DK14830861 T DK 14830861T DK 3049059 T3 DK3049059 T3 DK 3049059T3
Authority
DK
Denmark
Prior art keywords
headache
treatment
dhe formulation
intranasal
intranasal dhe
Prior art date
Application number
DK14830861.2T
Other languages
Danish (da)
English (en)
Inventor
Shunji Haruta
Nikhilesh N Singh
John Kollins
Salvador Rico
Original Assignee
Satsuma Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Satsuma Pharmaceuticals Inc filed Critical Satsuma Pharmaceuticals Inc
Application granted granted Critical
Publication of DK3049059T3 publication Critical patent/DK3049059T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK14830861.2T 2013-09-24 2014-09-24 Intranasal dhe formulering til behandlingen af hovedpine DK3049059T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361881947P 2013-09-24 2013-09-24
PCT/IB2014/002706 WO2015044782A2 (en) 2013-09-24 2014-09-24 Intranasal dhe for the treatment of headache

Publications (1)

Publication Number Publication Date
DK3049059T3 true DK3049059T3 (da) 2022-01-31

Family

ID=52424045

Family Applications (1)

Application Number Title Priority Date Filing Date
DK14830861.2T DK3049059T3 (da) 2013-09-24 2014-09-24 Intranasal dhe formulering til behandlingen af hovedpine

Country Status (6)

Country Link
US (5) US20160228433A1 (enExample)
EP (2) EP3049059B1 (enExample)
JP (2) JP2016531850A (enExample)
DK (1) DK3049059T3 (enExample)
ES (1) ES2904570T3 (enExample)
WO (1) WO2015044782A2 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101980738A (zh) 2008-02-07 2011-02-23 华盛顿大学 圆周气雾设备
EP2680913B1 (en) 2011-03-03 2020-05-06 Impel NeuroPharma Inc. Nasal drug delivery device
CN107376071B (zh) 2011-05-09 2021-07-09 英倍尔药业股份有限公司 用于将化合物递送到使用者的上部嗅觉区的喷嘴
HK1222358A1 (zh) 2013-04-28 2017-06-30 Impel Neuropharma Inc. 医用单位剂量容器
EP3049059B1 (en) 2013-09-24 2021-11-03 Satsuma Pharmaceuticals, Inc. Intranasal dhe formulation for the treatment of headache
EP3341059B1 (en) 2015-09-10 2022-03-02 Impel NeuroPharma Inc. In-line nasal delivery device
CA3030359A1 (en) 2016-08-05 2018-02-08 Shin Nippon Biomedical Laboratories, Ltd. Intranasal pharmaceutical powder compositions
BR112019027508A2 (pt) * 2017-07-02 2020-07-07 Dr. Reddys Laboratories Limited formas de dosagem nasal de di-hidroergotamina
US11571532B2 (en) 2017-11-21 2023-02-07 Impel Pharmaceuticals Inc. Intranasal device with dip tube
US11395887B2 (en) 2017-11-21 2022-07-26 Impel Pharmaceuticals Inc. Intranasal device with inlet interface
EP3735223A4 (en) 2018-01-05 2021-10-13 Impel Neuropharma Inc. INTRANASAL ADMINISTRATION OF OLANZAPINE BY A PRECISION OLFACTORY DEVICE
BR112020013744A8 (pt) * 2018-01-05 2022-10-18 Impel Neuropharma Inc Dispensação intranasal de di-hidroergotamina por dispositivo olfativo de precisão
JP2021532098A (ja) 2018-07-19 2021-11-25 インペル ニューロファーマ インコーポレイテッド パーキンソン病の治療のためのレボドパおよびドーパデカルボキシラーゼ阻害剤の呼吸管路送達
CA3122396A1 (en) 2018-12-11 2020-06-18 Satsuma Pharmaceuticals, Inc. Compositions, devices, and methods for treating or preventing headaches
CN113473967B (zh) 2019-01-03 2022-09-09 英倍尔制药公司 经鼻药物递送装置
AU2020277313A1 (en) 2019-05-17 2022-01-20 Impel Pharmaceuticals Inc. Single-use nasal delivery device
IL324950A (en) * 2023-05-31 2026-01-01 Shin Nippon Biomedical Laboratories Ltd Compositions for enhanced mucosal penetration

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2750090A1 (de) 1976-11-19 1978-06-01 Sandoz Ag Neue verabreichungsformen fuer organische verbindungen
US5169849A (en) * 1982-02-01 1992-12-08 Sandoz Ltd. Nasal pharmaceutical compositions
JPS59163313A (ja) * 1983-03-09 1984-09-14 Teijin Ltd 経鼻投与用ペプチドホルモン類組成物
DE69434304T2 (de) * 1993-03-26 2005-12-29 Merkus, Franciscus Wilhelmus H.M. Pharmazeutische Zusammensetzungen zur intranasalen Verabreichung von Dihydroergotamin
JP3197221B2 (ja) * 1996-02-27 2001-08-13 帝人株式会社 吸収性が改善された粉末状経鼻投与組成物
SE9803770D0 (sv) 1998-11-05 1998-11-05 Astra Ab Dry powder pharmaceutical formulation
AU7685200A (en) * 1999-10-12 2001-04-23 Kaken Pharmaceutical Co., Ltd. Powdery inhalational preparations and process for producing the same
EP1397173A1 (en) * 2001-06-20 2004-03-17 Nektar Therapeutics Powder aerosolization apparatus and method
MXPA03005980A (es) * 2001-07-05 2003-09-10 Translational Res Ltd Composiciones para administracion nasal de insulina.
US20030044458A1 (en) 2001-08-06 2003-03-06 Curtis Wright Oral dosage form comprising a therapeutic agent and an adverse-effect agent
FR2834212B1 (fr) * 2001-12-27 2004-07-09 Besins Int Belgique Utilisation d'une poudre a liberation immediate dans des compositions pharmaceutiques et nutraceutiques
JP4212019B2 (ja) * 2002-01-09 2009-01-21 Translational Research 株式会社 薬物の経鼻投与用組成物
GB0228826D0 (en) * 2002-12-11 2003-01-15 Okpala Joseph Hair technology in creating particles with improved delivery capabilities
US7638138B2 (en) * 2003-02-21 2009-12-29 Translational Research, Ltd. Compositions for nasal administration of pharmaceuticals
GB0304636D0 (en) * 2003-02-28 2003-04-02 Britannia Pharmaceuticals Ltd Pharmaceutical composition for nasal delivery
EP1663159A4 (en) 2003-09-10 2010-06-09 Map Pharmaceuticals Inc AEROSOL FORMULATIONS FOR THE DELIVERY OF DIHYDROERGOTAMINE TO THE SYSTEMIC CIRCULATION BY PULMONARY INHALATION
WO2006016530A1 (ja) * 2004-08-10 2006-02-16 Translational Research, Ltd. 速効性でかつ高い吸収性を可能とする経鼻投与用組成物
JP5694643B2 (ja) * 2005-08-05 2015-04-01 スリーエム イノベイティブ プロパティズ カンパニー 改善された流動性を示す組成物
WO2007066646A1 (ja) * 2005-12-06 2007-06-14 Asahi Kasei Chemicals Corporation 高速直接打錠による錠剤の製造方法
ES2652415T3 (es) * 2006-12-26 2018-02-02 Shin Nippon Biomedical Laboratories, Ltd. Preparación para aplicación transnasal
PL2425820T3 (pl) 2007-02-11 2015-08-31 Map Pharmaceuticals Inc Sposób terapeutycznego stosowania dhe w celu umożliwienia szybkiego złagodzenia migreny przy jednoczesnym zminimalizowaniu profilu działań niepożądanych
JP2009076785A (ja) * 2007-09-21 2009-04-09 Panasonic Corp 半導体装置の製造方法
US20110082150A1 (en) 2008-02-11 2011-04-07 Robert Owen Cook Headache pre-emption by dihydroergotamine treatment during headache Precursor events
US9101539B2 (en) * 2009-05-15 2015-08-11 Shin Nippon Biomedical Laboratories, Ltd. Intranasal pharmaceutical compositions with improved pharmacokinetics
US20110171141A1 (en) * 2009-06-26 2011-07-14 Kellerman Donald J Administration of dihydroergotamine mesylate particles using a metered dose inhaler
US8827946B2 (en) 2009-07-31 2014-09-09 Shin Nippon Biomedical Laboratories, Ltd. Intranasal granisetron and nasal applicator
SG181896A1 (en) 2009-12-23 2012-07-30 Map Pharmaceuticals Inc Novel ergoline analogs
EP2689785B1 (en) * 2010-04-15 2021-05-19 Shin Nippon Biomedical Laboratories, Ltd. Method for generating dry vaccine powder formulation for inranasal delivery
WO2011163600A2 (en) * 2010-06-25 2011-12-29 Apt Pharmaceuticals, Inc. Tacrolimus compositions for aerosol administration
ES2659761T3 (es) 2011-01-31 2018-03-19 Shin Nippon Biomedical Laboratories, Ltd. Dispositivos de administración intranasal
EP2680913B1 (en) 2011-03-03 2020-05-06 Impel NeuroPharma Inc. Nasal drug delivery device
EP2787970B1 (en) * 2011-12-11 2018-04-11 Recro Pharma, Inc. Intranasal dexmedetomidine compositions and methods of use thereof
US20140179705A1 (en) 2012-12-21 2014-06-26 Map Pharmaceuticals, Inc. 8'-hydroxy-dihydroergotamine compounds and compositions
EP2935280A4 (en) 2012-12-21 2016-05-25 Map Pharmaceuticals Inc 8'-HYDROXY-DIHYDROERGOTAMINE COMPOUNDS AND COMPOSITIONS
EP3049059B1 (en) 2013-09-24 2021-11-03 Satsuma Pharmaceuticals, Inc. Intranasal dhe formulation for the treatment of headache
US9561177B2 (en) 2014-03-14 2017-02-07 Adapt Pharma Limited Nasal drug products and methods of their use
CA3030359A1 (en) 2016-08-05 2018-02-08 Shin Nippon Biomedical Laboratories, Ltd. Intranasal pharmaceutical powder compositions
JP7523879B2 (ja) 2016-10-31 2024-07-29 エスエス製薬株式会社 医薬組成物
BR112019027508A2 (pt) 2017-07-02 2020-07-07 Dr. Reddys Laboratories Limited formas de dosagem nasal de di-hidroergotamina
US11744967B2 (en) 2017-09-26 2023-09-05 Shin Nippon Biomedical Laboratories, Ltd. Intranasal delivery devices
BR112020013744A8 (pt) 2018-01-05 2022-10-18 Impel Neuropharma Inc Dispensação intranasal de di-hidroergotamina por dispositivo olfativo de precisão
CA3122396A1 (en) 2018-12-11 2020-06-18 Satsuma Pharmaceuticals, Inc. Compositions, devices, and methods for treating or preventing headaches

Also Published As

Publication number Publication date
US20230000860A1 (en) 2023-01-05
JP6902583B2 (ja) 2021-07-14
US20240108619A1 (en) 2024-04-04
EP4008307A1 (en) 2022-06-08
JP2020007342A (ja) 2020-01-16
US20200179379A1 (en) 2020-06-11
US20160228433A1 (en) 2016-08-11
WO2015044782A2 (en) 2015-04-02
WO2015044782A3 (en) 2015-06-11
ES2904570T3 (es) 2022-04-05
JP2016531850A (ja) 2016-10-13
US12594273B2 (en) 2026-04-07
EP3049059A2 (en) 2016-08-03
EP3049059B1 (en) 2021-11-03
US20190275036A1 (en) 2019-09-12

Similar Documents

Publication Publication Date Title
DK2983787T3 (da) Fremgangsmåde til behandling af posttraumatisk stresssygdom
DK3080100T3 (da) Hæmmere af lysinspecifik demethylase-1
DK3603794T3 (da) Fremgangsmåde til overflader med gelmønster
DK3192902T3 (da) Fremgangsmåde til fremstilling af graphenholdige viscosefibre
DK2994238T3 (da) Belægningsanordning til termisk belægning
DK3096741T3 (da) Fremgangsmåde til fremstillingen af hybridosomer
IL243577A0 (en) Formulation of syk inhibitors
DK2954051T3 (da) Modificeret kapsid til genoverførsel til behandling af nethinden
HRP20180460T1 (hr) Inhibitori syk
HUE042443T2 (hu) GPR6 tetrahidropiridopirazin-modulátorai
HUE036383T2 (hu) Bevonási eljárás
PL3427584T3 (pl) Sposób zwalczania rdzy
DK3013544T3 (da) Fremgangsmåde til betonfremstilling
DK2992104T3 (da) Fremgangsmåde til ekspression
DK3007695T3 (da) Sammensætninger og fremgangsmåder til behandling af anæmi
DK3174858T3 (da) Fremgangsmåde til fremstilling af pyrazoler
LT3511319T (lt) Lizinui specifinės demetilazės-1 inhibitoriai
DK3010895T3 (da) Fremgangsmåde til fremstilling af 4-propargyleret aminobenzoxazinoner
DK3393744T3 (da) Fremgangsmåde til at danne en artikel
PT2953948T (pt) Antagonistas de integrina fluorada
DK3021839T3 (da) Sammensætninger for behandling af fibrose
DK2836460T3 (da) Fremgangsmåde til fremstilling af graphen
DK3288944T3 (da) Imidazopyrazinoner som pde1-inhibitorer
DK3022361T4 (da) Rambuk og fremgangsmåde til anvendelse deraf
HRP20181122T1 (hr) Postupak za pripremu jopamidola